GeneNews has entered into a marketing partnership agreement with Enzo Clinical Labs (Enzo) for the exclusive rights to market ColonSentry in New York and New Jersey. ColonSentry is a blood test for colorectal cancer.
Enzo will validate and seek approval of the ColonSentry test pursuant to New York, New Jersey and CLIA requirements, in addition to marketing and securing third party reimbursement for the test. Commercial terms were not disclosed. Enzo is projecting the US launch of ColonSentry in the second half of 2010.
Kevin Krenitsky, president of Enzo, said: “We are pleased to be working with GeneNews as their exclusive marketing partner in our key territories for this groundbreaking test which offers patients a novel, non-invasive option for determining an individual’s current risk for colorectal cancer.”
Gailina Liew, COO of GeneNews, said: “Enzo is our first US regional marketing partner and will provide an important segment of the eligible US population with access to our ColonSentry test. This marketing partnership is a key milestone achievement for GeneNews and follows the recent achievement of additional milestones including the publication of clinical validation data for ColonSentry and the issuance of a core US patent for our Sentinel Principle platform technology.
“In line with our ColonSentry commercialisation strategy, we are actively engaged in discussions with potential marketing partners in other US regions, Europe and Asia to provide global access to ColonSentry.”